A couple of years back, Lok et al. presented a new concept to treat ER+ metastatic BC patients using venetoclax (a potent and selective BCL2 inhibitor that has shown increased apoptotic response and achieved FDA approval in the CLL (chronic lymphocytic leukemia), SLL, (small lymphocytic lymphoma), and AML (acute myeloid leukemia) settings) [41]. The gene discussed is BCL2; the disease is breast cancer.